The i.v. application of CD362+ MSCs resulted in reduced cardiomyocyte stiffness paralleled by elevated NO and cGMP levels and increased arteriole density in a model of early-onset diabetic cardiomyopathy without fibrosis. Here, SDC2 is linked to diabetic cardiomyopathy.